Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 24;75(1):e888-e891.
doi: 10.1093/cid/ciab938.

A Higher Antibody Response Is Generated With a 6- to 7-Week (vs Standard) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Dosing Interval

Brian Grunau  1   2   3 , Michael Asamoah-Boaheng  2   4 , Pascal M Lavoie  5 , Mohammad Ehsanul Karim  1   6 , Tracy L Kirkham  7   8 , Paul A Demers  6   7   8 , Vilte Barakauskas  9 , Ana Citlali Marquez  9   10 , Agatha N Jassem  9   10 , Sheila F O'Brien  11 , Steven J Drews  11   12 , Scott Haig  3 , Sheldon Cheskes  13 , David M Goldfarb  9
Affiliations

A Higher Antibody Response Is Generated With a 6- to 7-Week (vs Standard) Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Dosing Interval

Brian Grunau et al. Clin Infect Dis. .

Abstract

The optimal dosing interval for severe acute respiratory syndrome coronavirus 2 vaccines remains controversial. In this prospective study, we compared serology results of paramedics vaccinated with mRNA vaccines at the recommended short (17-28 days) vs long (42-49 days) interval. We found that a long dosing interval resulted in higher spike, receptor binding domain, and spike N terminal domain antibody concentrations.

Keywords: COVID-19; SARS-CoV-2; antibodies; spike; vaccine.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Scatterplot of MSD spike (A, Au/mL), Roche spike (B, U/mL), and MSD RBD (C, Au/mL) antibody concentrations, with cubic spline curves (and 95% confidence intervals). For the Roche spike assay, the maximum value of 2500 U/L occurred in 35 (30%) samples of the short interval group and 60 (88%) samples of the long interval group. Abbreviations: MSD, Meso scale discovery; RBD, receptor binding domain.
See this image and copyright information in PMC

References

    1. Polack FP, Thomas SJ, Kitchin N, et al. ; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383:2603–15. - PMC - PubMed
    1. Baden LR, El Sahly HM, Essink B, et al. . Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021; 384:403–16. - PMC - PubMed
    1. Voysey M, Costa Clemens SA, Madhi SA, et al. . Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 2021; 397:881–91. - PMC - PubMed
    1. Ainsworth M, Andersson M, Auckland K, et al. . Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infect Dis 2020; 20:1390–400. - PMC - PubMed
    1. Ebinger JE, Fert-Bober J, Printsev I, et al. . Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med 2021; 27:981–4. - PMC - PubMed

Publication types